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Toll-like receptors (TLRs) play key roles in detecting pathogens and
initiating inﬂammatory responses that, subsequently, prime speciﬁc
adaptive responses. Several mechanisms control TLR activity to avoid
excessive inﬂammation and consequent immunopathology, including
the anti-inﬂammatory cytokine IL-10. Recently, several TLR-respon-
sive microRNAs (miRs) have also been proposed as potential regu-
lators of this signaling pathway, but their functional role during the
inﬂammatory response still is incompletely understood. In this study,
we report that, after LPS engagement, monocytes up-regulate miR-
146b via an IL-10–mediated STAT3-dependent loop. We show evi-
dence that miR-146bmodulates the TLR4 signaling pathway by direct
targeting of multiple elements, including the LPS receptor TLR4 and
the key adaptor/signaling proteins myeloid differentiation primary re-
sponse (MyD88), interleukin-1 receptor-associated kinase 1 (IRAK-1),
and TNF receptor-associated factor 6 (TRAF6). Furthermore, we
demonstrate that the enforced expression of miR-146b in human
monocytes led to a signiﬁcant reduction in the LPS-dependent pro-
duction of several proinﬂammatory cytokines and chemokines, in-
cluding IL-6, TNF-α, IL-8, CCL3, CCL2, CCL7, and CXCL10. Our results
thus identify miR-146b as an IL-10–responsive miR with an anti-in-
ﬂammatory activity based on multiple targeting of components of
the TLR4 pathway in monocytes and candidate miR-146b as a mo-
lecular effector of the IL-10 anti-inﬂammatory activity.
Toll-like receptors (TLRs) have important roles in detectingpathogens and initiating inﬂammatory responses that, sub-
sequently, prime speciﬁc adaptive immune responses during in-
fection (1). It is therefore important that TLR signaling pathways
are tightly regulated. One of the most effective suppressor of TLR-
induced inﬂammatory cytokine production is IL-10, which displays
powerful inhibitory actions on innate immune cells (2,3), not only
by direct inhibition of cytokine transcription (4,5) but also by
destabilizing their coding RNA (6) and blocking their translation
(7). MicroRNAs (miRs) are small (22–24 nt) noncoding RNA se-
quences acting primarily as translational repressors of gene tran-
scripts by interacting with their 3′ UTRs (8,9). In the ﬁeld of
inﬂammation, miRs are attracting increasingly interest for their
ability to regulate strength and timing of TLR responses (10). Al-
though their role in the resolution of inﬂammation is just beginning
to be explored, their emerging importance in the modulation of
TLR signaling strongly suggests a possible regulation of their ex-
pression by anti-inﬂammatory stimuli. In this respect, IL-10 has
been recently shown to inhibit miR-155 induction by TLRs (11),
thus increasing the expression of the miR-155 target gene SH2
domain-containing inositol-5′-phosphatase 1 (SHIP1) and pro-
moting expression of anti-inﬂammatory genes (12). Moreover,
a direct role of miR-187 in IL-10–mediated suppression of proin-
ﬂammatory cytokines has been recently demonstrated (13), and
miR-21 has been reported to promote an anti-inﬂammatory re-
sponse by increasing IL-10 production through the down-regula-
tion of programmed cell death 4 (PDCD4) (14). We here report
that LPS induces expression of miR-146b via an IL-10–dependent
loop, and demonstrate that miR-146b play an anti-inﬂammatory
role in monocytes by direct targeting multiple elements involved in
the TLR4 signaling pathway, thus making this miR a candidate
feedback modulator of the LPS response potentially involved in
inﬂammation resolution.
Results
MiR-146b Expression Is Induced by IL-10 in Human Monocytes. TLRs
have been shown to regulate a distinct panel of miR in monocytes,
including miR-155 andmiR-146a (15-17).We have here identiﬁed
miR-146b, a second member of the miR-146 family located within
an intergenic region on chromosome 10, as an LPS-responsive
miR induced at a later time point compared with miR-146a and
miR-155 (Fig. 1A). MiR-146b induction by LPS was also mirrored
by its enrichment in the RNA-induced silencing complex (RISC),
suggesting its functional role in human primary monocytes (Fig.
S1A). Analysis of miR-146b expression in monocytes stimulated
with IL-1β and different TLR agonists, including the TLR2 agonist
palmitoyl-3-cysteine-serine-lysine 4 (Pam3CsK4), the TLR3 ago-
nist poly(I:C), the TLR7 agonist imiquimod, and the TLR9 agonist
synthetic CpG oligonucleotides (ODN), showed that miR-146b
induction is restricted to the signaling pathway activated by IL-1β
and TLR2/TLR4 (Fig. S2A). As the ability of different stimuli to
induce miR-146b directly correlates with their ability to induce
IL-10 production (Fig. S2B), we asked whether IL-10 could be
involved in the induction of miR-146b by LPS. As shown in Fig.
1B, IL-10 stimulation induced miR-146b but was unable to induce
expression of miR-146a and miR-155, and suppressed the LPS-
dependent induction of miR-155, as previously reported (11).
Consistent with these results, the inhibition of the LPS-induced
endogenous IL-10 by using an anti–IL-10 receptor blocking
monoclonal antibody or the JAK/STAT inhibitor AG-490 (18)
resulted in a signiﬁcant reduction of miR-146b induction by LPS,
whereas miR-146a expression was not affected andmiR-155 levels
were further increased (Fig. 2 A–C). Finally, the LPS-dependent
induction of miR-146b observed in murine bone marrow-derived
macrophages was severely reduced when macrophages were
obtained from IL-10−/− animals, indicating that, also in the murine
system, miR-146b is induced by LPS via an IL-10–dependent
feedback loop. Conversely, miR-146a induction by LPS was not
signiﬁcantly different in WT and IL-10−/− macrophages, further
demonstrating the IL-10 dependency of miR-146b and not miR-
146a (Fig. 1C).
The human mature miR-146b is generated by processing of the
premiR-146b molecule transcribed from an intergenic region on
chromosome 10, with the predicted transcription start site located
700 bp upstream of the mature miR-146b sequence (15). To gain
additional insight into the role of IL-10 in the transcriptional
regulation of miR-146b in monocytes, the recruitment of poly-
merase II (Pol II) to the miR-146b promoter region in the pres-
ence of LPS or IL-10 was investigated. As expected, ChIP analysis
indicated that, in LPS-stimulated monocytes, Pol II was recruited
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to the miR-146b promoter, as well as to the miR-146a and miR-
155 promoters (Fig. 2 D–F). Conversely, in monocytes stimulated
with IL-10, Pol II recruitment was observed only on the promoter
region of miR-146b and not miR-146a or miR-155, consistent with
the selective IL-10–mediated up-regulation of miR-146b expres-
sion (Fig. 2 D–F). To identify putative cis-regulatory elements
critical for IL-10–dependent gene transcription, a comparative
bioinformatic analysis covering 1,000 bp upstream of the premiR-
146b coding region was performed. Conserved putative binding
sites for STAT3, the main transcription factor mediating the
IL-10 anti-inﬂammatory action in monocytes (19), were predicted
on both miR-146a and miR-146b promoter regions (Fig. 2G);
however, ChIP analysis on monocytes stimulated with IL-10
showed an IL-10–dependent signiﬁcant recruitment of STAT3
protein on the region encompassing the two predicted STAT3
binding sites exclusively in the miR-146b promoter region,
whereas no STAT3 recruitment was found on the miR-146a
promoter region (Fig. 2H). In the miR-146b promoter region,
two putative NF-κB binding sites were also predicted. Inter-
estingly, the NF-κB chemical inhibitors caffeic acid phenetyl ester
(CAPE) and pyrrolidine dithiocarbamate (PDTC) signiﬁcantly
inhibited miR-146a expression levels, consistent with previous
reports of NF-κB driving the expression of miR-146a in LPS-
stimulatedmonocytes (15), but had no role onmiR-146b induction
by LPS in monocytes (Fig. 2I). These data indicate that miR-146a
and miR-146b undergo a profound different regulation in mon-
ocytes exposed to pro- and anti-inﬂammatory stimuli and identify
miR-146b, but not miR-146a, as an IL-10–dependent miR, sug-
gesting that miR-146b may play a role in mediating the anti-
inﬂammatory activity of IL-10.
The TLR/IL-1 Receptor Signaling Pathway as a miR-146b Target. To
gain insight into the functional role of miR-146b in the context of
LPS-mediated inﬂammation, we chose an in silico approach to
identify potential miR-146b targets. As algorithms based on seed
pairing and evolutionary conservation typically have low speciﬁcity
predictive value, we combined miRanda (20) predictions with
pathways analysis based on the Ingenuity Pathway Analysis data-
base (www.ingenuity.com), mapping biomolecular networks based
on known pathways, GeneOntology, and interactions. Interestingly,
miR-146b targets showed signiﬁcant enrichment in “TLR sig-
naling,” “NF-κB signaling,” and “IL-1β signaling” pathways (Fig.
3), leading us to investigate the hypothesis that miR-146b may
contribute to the IL-10-dependent feedback inhibitory loop ﬁne
Fig. 1. IL-10 induces miR-146b expression. Ex-
pression levels of miR-146a (white symbols), miR-
146b (black symbols), and miR-155 (gray symbols)
were measured by qPCR in triplicate samples of
human monocytes cultured for the indicated times
with 100 ng/mL LPS (A) or with 20 ng/mL IL-10 (B).
Results are expressed as fold change vs. untreated
cells (mean ± SEM; n = 3). (C ) Bone marrow-de-
rived macrophages from WT (solid line) or IL-10−/−
mice (dashed line) were stimulated or not stimu-
lated for the indicated time with 100 ng/mL LPS,
and expression of miR-146b (closed symbols) and
miR-146a (open symbols) was quantiﬁed by qPCR in triplicate samples. Results expressed as fold change vs. untreated cells (mean ± SEM; n = 3).
Fig. 2. MiR-146b induction after LPS challenge is
driven by IL-10. (A–C) Human monocytes were pre-
treated or not pretreated for 30 min with 5 μM of
the JAK/STAT inhibitor AG-490 and then stimulated
for 12 h with 100 ng/mL LPS. Alternatively, mono-
cytes stimulated for 12 h with 100 ng/mL LPS were
cultured in the presence of 10 μg/mL anti-IL-10 re-
ceptor (-αIL-10R) or isotype control mAb. MiR levels
were measured by qPCR in triplicate samples and
results expressed as fold change vs. control (mean ±
SEM; n = 3). ChIP assays were carried out by using
anti-Pol II Ab and analyzed by qPCR with speciﬁc
primers binding to the miR-146b, miR-146a, and
miR-155 promoters (D, E, and F, respectively). Data
from qPCR have been normalized to input DNA and
displayed as fold change vs. untreated cells (mean ±
SEM; n = 3). (G) Graphical representation of pre-
dicted promoter regions reporting binding sites of
transcription factors of potential interest. (H) Mon-
ocytes were stimulated or not stimulated for 4 h
with 20 ng/mL IL-10. ChIP assays were carried out by
using anti-STAT3 Ab and analyzed by qPCR with
speciﬁc primers binding to miR-146a (white col-
umns) and miR-146b (black columns) promoters. (I)
Cells were pretreated for 1 h with the NF-κB inhib-
itors PDTC (1 μM) or CAPE (2 μM) and then stimu-
lated for 12 h with 100 ng/mL LPS. MiR-146a (white
columns) and miR-146b (black columns) expression
levels were measured by qPCR in triplicate samples
and results expressed as fold change vs. control
(mean ± SEM; n = 3).
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tuning the inﬂammatory response induced in monocytes by TLR/
IL-1 receptor (IL-1R) activation. In particular, miR-146b was
predicted to directly target both receptors and key signal trans-
ducers of the TLR/IL-1 signaling pathway but not effector mol-
ecules, with the remarkable exception of IL-6 (Fig. S3).
TLR4 Is a Direct Target of miR-146b. To validate predictions, the
direct targeting of TLR2 and TLR4 by miR-146b was inves-
tigated. In 293T cells, miR-146b signiﬁcantly decreased luciferase
activity of a reporter gene containing the TLR4 3′UTR, and the
deletion of 5 nt in the 3′UTR seed match sequence abolished the
inhibitory effect of miR-146b on luciferase levels, indicating that
the observed down-regulation was dependent on the predicted
miR-146b target site (Fig. 4A). The signiﬁcant enrichment of
TRL4 mRNA in the RISC complexes immunoprecipitated from
human monocytic THP-1 cells transduced with the lentiviral-
based expression vector pRRL-miR146b, compared with THP-1
cells transduced with the control lentiviral construct pRRL-ctrl,
provide direct evidence that miR-146b directly targets TLR4 (Fig.
4B). Consistent with this, pRRL-146b–transduced THP-1 cells
showed a signiﬁcant decrease of TLR4 protein levels compared
with THP-1 cells transduced with pRRL-ctrl [mean ﬂuorescence
intensity (MFI), pRRL-ctrl, 1,117 ± 120; pRRL-146b, 790 ± 98;
P < 0.05; Fig. 4C]. Protein reduction was not mirrored by a cor-
responding reduction at the transcript level (pRRL-ctrl, 0.040 ±
0.25; pRRL-146b, 0.044 ± 0.19, relative to GAPDH), indicating
that miR-146b acts by blocking translation of TLR4 mRNA. As
a complementary approach, we used lentiviral expression vectors
to obtain a permanent miR-146b inhibition (miRzip-146b), and
we found a signiﬁcant decrease of TLR4 transcript in the RISC
complex of LPS-stimulated THP-1 cells (Fig. 4B), also mirrored
by a corresponding increase of TLR4 protein in miRzip-146b cells
compared with miRzip-ctrl THP-1 cells (MFI, miRzip-ctrl, 3,616 ±
98; miRzip-146b, 5,323 ± 111; P < 0.05; Fig. 4D). Conversely,
miR-146b overexpression did not induce any impairment of the
TLR2 transcript stability as assessed by luciferase assay (Fig. 4E),
did not enrich TLR2 transcript in the RISC complex (Fig. 4F),
and did not reduce TLR2 protein expression (MFI, pRRL-ctrl,
1,671 ± 59; pRRL-146b, 1,530 ± 61; P value not signiﬁcant; Fig.
4G). In parallel experiments, THP-1 cells stimulated with LPS in
the presence of miRzip-146b did not show any increase of the
TLR2 transcript in the RISC complex (Fig. 4F), nor a decrease in
TLR2 protein expression compared with miRzip-ctrl THP-1 cells
(MFI, miRzip-ctrl, 1,001 ± 20; miRzip-146b, 1,186.5 ± 157; P
value not signiﬁcant; Fig. 4H). Taken together, these results in-
dicate that, contrary to predictions, TLR2 is not a direct target
of miR-146b.
Multitargeting of TLR Signaling Pathway by miR-146b. As the TLR/
IL-1R signaling pathway scored as a major target of miR-146b,
signaling adaptors involved in this pathway were investigated.
Luciferase assays validated myeloid differentiation primary re-
sponse 88 (MyD88), interleukin-1 recpetor-associated kinase 1
(IRAK-1), and TNF receptor-associated factor 6 (TRAF6) as di-
rect targets of miR-146b, and, in all cases, abrogation of miR-146b
effects by mutagenesis of its seed match regions in target 3′UTR
demonstrated the speciﬁcity of its action (Fig. 5 A, E, and I, re-
spectively). Consistent with this, RISC immunoprecipitation (RIP)
analysis revealed a signiﬁcant enrichment of MyD88, IRAK-1, and
TRAF6 transcripts in pRRL-146b–transduced THP-1 cells and
a corresponding reduction in THP-1 cells transduced with miRzip-
146b but not miRzip-ctrl (Fig. 5 B, F, andL, respectively). Western
blot analysis conﬁrmed that enforced expression of miR-146b re-
duced MyD88, IRAK-1, and TRAF6 protein levels (Fig. 5 C, G,
andM, respectively), whereas miR-146b inhibition enhanced their
protein expression levels (Fig. 5 D, H, and N). Conversely, even
though IL-6 was also predicted as a direct target of miR-146b,
luciferase assay on the IL-6 3′UTR and RIP assay did not conﬁrm
this prediction (Fig. 5 O and P, respectively). Quantitative real-
time PCR (qPCR) experiments revealed that miR-146b targeting
affected stability of MyD88 and TRAF6 but not IRAK-1 tran-
scripts, suggesting that, in this latter case, the miR-146b effect is
likely mediated by translation repression. Conversely, miR-146a
signiﬁcantly destabilized IRAK-1 and TRAF6 but not MyD88
transcript (Fig. S4 A–C). The predicted energy interactions of
miR-146a and miR-146b on their corresponding seeds on these
targets did not correlate with their effect on the transcripts’ sta-
bility (Fig. S4 A–C), indicating the involvement of other still un-
known parameters. Taken together, these results demonstrate that
miR-146b targets multiple elements involved in the TLR signaling
system, as previously described for miR-146a (15), but also in-
dicate that the two miR-146 isoforms adopt different mechanisms
to regulate TLR adaptors, suggesting they may exert different
functions on the TLR signaling pathway.
Fig. 3. miR-146b targets the TLR signaling pathway. Canonical pathways
signiﬁcantly enriched for miR-146b predicted target genes as identiﬁed by
the Ingenuity Pathways Analysis library.
Fig. 4. TLR4 is a direct target of miR-146b. (A and
E) Luciferase constructs with the entire 3′UTR of
TLR4 (luc-TLR4) or the corresponding construct mu-
tated in the miR-146b seed region (luc-mut-TLR4) or
TLR2 (luc-TLR2) were cotransfected in 293T cells with
miR-146b mimic or a negative control mimic (ctrl).
Results are expressed as the ratio between renilla
and ﬁreﬂy luciferase activities (mean percent varia-
tion ± SEM; n = 3). (B and F) Cell extracts from THP-1
cells transduced with pRRL-ctrl (CT; closed columns)
or pRRL-146b (146b; closed columns) or transduced
with miRzip-ctrl (CT; open columns) or miRzip-146b
(146b; closed columns) were subjected to RIP assay
by using anti-Ago2 or IgG control Abs, and levels of
TLR4 and TLR2 transcripts (B and F, respectively)
were assayed in triplicate by qPCR in RIP (IP AGO2) and leftover samples. Results are expressed as normalized fold enrichment (mean percent variation ± SEM;
n = 3). (C, D, G, and H) Protein levels were measured by ﬂow cytometry on THP-1 cells transduced with pRRL-ctrl (gray histogram) or pRRL-146b (black
histogram) (C and G, TLR4 and TRL2, respectively) or with miRzip-ctrl (gray) or miRzip-146b (black; D and H, TLR4 and TRL2, respectively). The isotype control
staining is shown by the white histogram. One experiment representative of four performed with similar results is shown.









MiR-146b Controls Induction of Proinﬂammatory Cytokines by TLR
Agonists. As we demonstrated a direct targeting of multiple ele-
ments involved in the TLR/IL-1R signaling pathway by miR-146b,
we investigated its biological impact on the TLR-dependent
production of proinﬂammatory cytokines. In THP-1 cells ex-
posed to LPS, we observed a signiﬁcant reduction of proin-
ﬂammatory cytokine and chemokines when miR-146b expression
was enhanced by cell transduction with pRRL-146b and a signiﬁcant
enhancement when miR-146b expression was inhibited by cell
transduction with miRzip-146b (Fig. 6 A–H). Similar results were
obtained when the TLR2 agonist Pam3CsK4 was used (Fig. S5).
Finally, we measured the effect of miR-146b on the production of
the IFN-inducible CXCL10 induced by LPS, mainly a secondary
consequence of TRIF-dependent IFN-β production, or IFN-γ,
which operates through the activation of a MyD88/IRAK-1–
independent STAT1-dependent pathway (21). Consistent with
the notion that miR-146b speciﬁcally operates on the TLR/IL-1R
signaling pathway, the induction of CXCL10 production by LPS
was signiﬁcantly impaired in pRRL-146b–transduced THP-1 cells
and enhanced in miRzip-146b–transduced THP1 cells (Fig. 6H),
whereas its induction by IFN-γ was unaffected (Fig. 6I). Taken
together, these data identify miR-146b as an anti-inﬂammatory
miR able to reduce the inﬂammatory signal transmitted through
the engagement of TLR4 by a multiple targeting mechanisms
directed to the receptor and its adaptor proteins.
Fig. 5. Multitargeting of the TLR4 signaling pathway by miR-146b. 3′UTR luciferase constructs were cotransfected in 293T cells with miR-146b mimic or
a negative control mimic (ctrl). MyD88 (A), IRAK-1 (E), TRAF6 (I), and IL-6 (M). Results are expressed as the ratio between renilla and ﬁreﬂy luciferase activities
(mean percent variation ± SEM; n = 3). Cell extracts from pRRL-ctrl–transduced (CT) or pRRL-146b–transduced (146b) THP-1 cells (white histograms); miRzip-
ctrl–transduced or miRzip-146b–transduced THP-1 cells (black histograms) were subjected to RIP assay by using anti-Ago2 or IgG control Abs. Levels of MyD88
(B), IRAK-1 (F), TRAF6 (J), and IL-6 (N) mRNAs were assayed in triplicate by qPCR in RIP (IP AGO2) and leftover samples and expressed as normalized fold
enrichment. (mean percent variation ± SEM; n = 3). Protein levels were analyzed by Western blot and normalized on tubulin, used as loading controls. MyD88
(C and D), IRAK-1 (G and H), and TRAF6 (K and L). One experiment representative of four is shown.
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Discussion
Negative regulation of the immune response plays an important
role in controlling homeostasis of the immune system and in
preventing development of autoimmune diseases. Multiple regu-
latory mechanisms, including a complex network of receptors,
transcription factors, adaptors, and effector molecules, have
evolved to keep activation of the immune system in check. Evi-
dence is now emerging indicating that miR might constitute an
additional negative feedback mechanism operating in the innate
immune system (22-24). MiR-146a has been the ﬁrst miR associ-
ated to the inﬂammatory response, described as an miR rapidly
induced by proinﬂammatory stimuli in phagocytes (15), and ex-
perimental evidence has clearly deﬁned its role of negative regu-
lator of inﬂammation (10, 25, 26) and its involvement in endotoxin
tolerance (27, 28). The miR-146 family also includes miR-146b,
which is encoded by a distinct gene on a separate chromosome and
only differs from miR-146a by 2 nt at the 3′ end in its mature se-
quence. Despite their sequence similarity, it is still unclear whether
these two miRs fulﬁll redundant or distinct functions. Unlike miR-
146a, little information is available on the biological role in the
context of the immune response of miR-146b, which has been
mostly associated with tumor biology, being expressed at lower
levels in many human solid tumors compared with normal tissues
(29–32).
Here we report that LPS stimulation induces miR-146b ex-
pression in human monocytes, with delayed kinetics with respect
to miR-146a. Most relevant, our study provides evidence for a link
between miR-146b and IL-10, demonstrating that miR-146b in-
duction depends on the activity of IL-10 produced after LPS
challenging, whereas, to the contrary, IL-10 does not inﬂuence
miR-146a expression. This is consistent with ChIP data showing
a central role of STAT3 in the induction of miR-146b but not miR-
146a, which instead depends upon NF-κB. Bioinformatic analysis
revealed a signiﬁcant enrichment of miR-146b potential targets in
the TLR signaling, IL-1 signaling, and NF-kB signaling pathways,
which play an essential role in the innate immune response driving
transcriptional activation of genes encoding for proinﬂammatory
cytokines and costimulatory molecules, which subsequently con-
trol the activation of antigen-speciﬁc adaptive immune responses.
Luciferase and RIP assays validated the LPS receptor TLR4 and
the proximal adaptor molecules MyD88, IRAK-1, and TRAF6 as
true miR-146b targets. As these molecules sustain the TLR4 sig-
naling pathway and showed a relatively mild down-regulation at
the protein level, these ﬁndings are consistent with the present
understanding that miRs might conceivably exert their major ac-
tivities through the subtle individual regulation of multiple targets
involved in a common signaling pathway rather then operating a
strong repression of isolated targets (29, 30). In keeping with this
mechanism of regulation, enforced expression of miR-146b re-
sulted in the marked reduction of proinﬂammatory cytokines
highly expressed upon TLR triggering. These ﬁndings suggest that
miR-146b mediates some of the anti-inﬂammatory activities of
IL-10 repressing the inﬂammatory response inmonocytes by direct
targeting of transcripts encoding TLR4 and key adaptors/signaling
molecules.
Although our results leave open the question whether the two
miR-146 isoforms are functionally equivalent, their divergent and
asynchronous transcriptional regulation suggests they play differ-
ential roles during distinct temporal windows of the inﬂammatory
process. During the development of the inﬂammatory process
miR-146a and b may represent the components of a relay team in
which one isoform succeeds to other to control expression of pro-
inﬂammatory genes, ﬁrst through the activity of the LPS-depend
induction of miR-146a, and subsequently during the resolution
phase maintaining transcripts repression through the IL-10 de-
pendent induction of miR-146b. In this respect it is worth noticing
that miR-146a–deﬁcient mice are indeed overresponsive to bac-
terial challenge and produce excessive amount of proinﬂammatory
cytokines (31), but they show an autoimmune phenotype with late
onset and incomplete penetrance and lack a global change in the
expression of putative miR-146 targets (32). This phenotype is
suggestive of the existence of a compensatory mechanism oper-
ating in miR-146a–deﬁcient animals. Finally, similar to miR-146b,
miR-146a has been shown to target IRAK-1 and TRAF6, although
in different cellular contexts (15, 29), but its ability to also directly
target MyD88 and TLR4 has not been investigated.
Further research is required to understand whether miR-146b
truly serves as a molecular switch involved in the resolution of
inﬂammation, but it is interesting to note that this miR has been
reported to be expressed during the resolution phase in a murine
model of acute inﬂammation (33). A broader and deeper un-
derstanding of how miR-146b acts in concert with the growing
number of negative regulators, particularly in the context of
complex inﬂammatory processes involving signaling by multiple
receptors, may well lead to novel therapeutic approaches for the
rapidly expanding number of diseases driven by dysregulated
inﬂammatory responses.
Materials and Methods
Materials. A detailed list of materials is provided in SI Materials and Methods.
Cell Puriﬁcation and Culture. Human monocytes were obtained from healthy
donor buffy coats by two-step gradient centrifugation using Ficoll (Bio-
chrom) and Percoll (Amersham). Human studies were approved by the eth-
ical committee of Istituto Clinico Humanitas, Milan, Italy. Monocytes and
THP-1 cell line (American Type Culture Collection) were resuspended in RPMI
1640 (Lonza) supplemented with 10% (vol/vol) heat-inactivated FBS (Lonza),
100 U/mL penicillin/streptomycin (Lonza), and 25 mML-glutamine (Lonza).
The HEK-293T cell line (American Type Culture Collection) was grown in
Dulbecco’s modiﬁed Eagle medium (DMEM) (Cambrex) supplemented with
10% (vol/vol) FBS, 100 U/mL penicillin/streptomycin, and 25 mM L-glutamine.
Murine bone marrow-derived macrophages were obtained as described in SI
Materials and Methods.
ChIP Assay. ChIP experiments were performed as described elsewhere (34)
and in SI Materials and Methods.
Fig. 6. MiR-146b down-regulates TLR4-dependent production of proin-
ﬂammatory cytokines. (A–H) Proinﬂammatory cytokine levels measured by
ELISA in cell-free supernatants of THP-1 cells transduced with lentiviral
vectors overexpressing miR-146b (pRRL-146b and its respective control) or
a miR-146b sponge (miRzip-146b and its respective control) after stimulation
with 1 μg/mL LPS. (I) CXCL10 levels measured by ELISA in cell-free super-
natants collected under the same experimental conditions after stimulation
with 10 ng/mL IFN-γ.









ELISA. Antibodies and detection reagents for ELISAs were purchased from
R&D Systems and used according to the manufacturer’s instructions. Samples
were diluted so that the optical density fell within the optimal portion of
a log standard curve.
Quantiﬁcation of miR and mRNA. Total RNA was puriﬁed by using TRIzol Re-
agent (Ambion), and qPCR was conducted by using a 7900HT Real-Time PCR
System. One hundred nanograms of total RNA were reverse-transcribed for
quantiﬁcation of miR expression by using TaqMan MiRNA Reverse Transcrip-
tion Kit (Applied Biosystems), according to themanufacturer’s instructions and
as described in detail in SI Materials and Methods.
Constructs. The 3′UTR of TLR4, TLR2, MyD88, IRAK-1, TRAF6, and IL-6 were
ampliﬁed from genomic DNA and cloned in the biosensor psiCHECK-2 vector
(Promega). PremiR-146b and premiR-146a were ampliﬁed from genomic
DNA and cloned in the pcDNA3 expression vector as described in SI Materials
and Methods. To knock down miR-146b expression, the miRzip lentivector-
based construct anti–miR-146b and the relative control were purchased from
System Biosciences. The list of oligonucleotides used is reported in Table S1.
Luciferase Reporter Assay. HEK-293T cells were transfected after 24 h with
100 ng psiCHECK-2–3′UTR reporter construct and 700 ng pcDNA3-miR or
pcDNA3 as control, by using Lipofectamine 2000 (Invitrogen), according
to the manufacturer’s protocol, as described in detail in SI Materials
and Methods.
FACS Analysis. Cells were washed twice with PBS solution containing 1% BSA.
Aspeciﬁc bindingwas blocked by using Fc-block (BD Biosciences).Washed cells
were resuspended in a 1:200 dilution of APC-conjugated anti-human TLR4
(clone HTA125; eBioscience) or anti-human TLR2 antibody (clone 383936; R&D
Systems) or the mouse IgG2a isotype control APC (eBioscience). Stained cells
were washed twice with PBS solution containing 1% BSA and analyzed by
ﬂow cytometry (FACSCanto; BD Biosciences).
Immunoprecipitation of Ago2-Bound RNAs. Immunoprecipitation of Ago2-
bound RNAs (RIP), which contains miRs and their targetmRNA, was performed
as previously described (35), with minor modiﬁcations and as described in
detail in SI Materials and Methods. Brieﬂy, 30 × 106 pRRL-ctrl and pRRL-146b
THP-1 cells were stimulated for 2 h with 1 μg/mL LPS, whereas miRzip-ctrl and
miRzip-146b THP-1 cells were stimulated for 12 h with 1 μg/mL LPS. In all
experiments, an aliquot of immunoprecipitation supernatants, corresponding
to 0.5 × 106 cell equivalent, was removed after immunoprecipitation (in-
dicated as “left over”) and used as control for the speciﬁcity of the assay.
Results were expressed as fold enrichment relative to Ago2-immunoprecipi-
tation control samples.
Statistical Analysis. Statistical evaluation was performed with use of the
Student t test or one-way ANOVA and reported in ﬁgures. P values less than
0.05 were considered signiﬁcant.
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